First Allied Advisory Services’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

First Allied Advisory Services’s Portfolio SIOX Stock Details SIOX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-1,875	Closed	-$34K	–	1248
2018 Q2	$34K	Buy	+1,875	New	+$27.7K	﹤0.01%	1136

Other funds holding SIOX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

First Allied Advisory Services's SIOX Position: Q3 2018 in Review

First Allied Advisory Services sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q3 2018, closing a stake of 1,875 shares — an estimated $34K sold.

First Allied Advisory Services first reported a position in SIOX in Q2 2018 and held it in 1 quarter. The position peaked at $34K in Q2 2018. 61 funds tracked by Wall St. Rank hold SIOX as of Q3 2018.

First Allied Advisory Services reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
First Allied Advisory Services sold 1,875 Sio Gene Therapies Inc. Common Stock shares in Q3 2018, an estimated $34K.
First Allied Advisory Services first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2018 and held it in 1 quarter.
First Allied Advisory Services's Sio Gene Therapies Inc. Common Stock position peaked at $34K in Q2 2018.
61 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q3 2018.

Based on First Allied Advisory Services's 13F filing for Q3 2018, filed 14 Nov 2018.